January 9, 2026 - Glafabra Therapeutics, a biotechnology company pioneering long-lasting gene therapies for lysosomal storage disorders, announced today that it has reached a significant halfway milestone in its pre-seed financing round. The round is led by Rogue Funds is leading our pre-seed round and has made a significant commitment bringing us to more than 75% raised in Glafabra’s pre seed, at its $5M cap Tranche I SAFEs (Tranche II SAFEs will be for $500,000 at $12M cap). The commitment by Rogue Funds significantly accelerates Glafabra’s mission to translate clinical success in Canada into an open IND in U.S.

Fabry program is now on track to start clinical trials at the University of Utah Health in mid 2027.

The new capital is earmarked for three critical pillars of development:

1. Securing Orphan Drug Designation.

2. Facilitating an INTERACT meeting with the FDA.

3. Refining the optimal CMC (manufacturing pathway) for the company’s proprietary cell therapy platform.

Redefining the Standard of Care

Glafabra’s lead asset, GT-GLA-S03, targets Fabry disease—a condition currently managed by Enzyme Replacement Therapy (ERT). ERT requires patients to undergo high-frequency protein infusions every two weeks, often referred to as the "jab-for-the-IV-bag," forcing them to schedule their lives around tedious clinical visits.

Glafabra’s Live-cel™ infusions utilize a patient’s own cells to provide a redosable treatment that lasts significantly longer. Based on clinical data, patients may only require a repeat procedure every five years, offering a 130x improvement in duration over the current standard of care.

"This partnership with Rogue Funds provides the critical funding to help us de-risk clinical trial implementation in the U.S.," said Dr. Chris Hopkins, CEO of Glafabra. "With Live-cel, patients get their time back. Instead of bi-weekly infusions, they can look forward to years of freedom to travel and spend time with family without the burden of constant clinical intervention."

Strategic Alignment

The investment marks a strong vote of confidence in Glafabra's leadership and technical approach. Jacob Rowe, Chief Investment Officer at Rogue Funds, noted: "The team at Glafabra is first class. We are excited to work with them and their board to find the most efficient path to the clinic for their therapeutic products."

Sidney Norton, acting Chief Financial Officer for Glafabra, added: "These funds are a critical component of our 2026 Proforma. They allow us to accelerate activities toward an open Investigational New Drug (IND) application, keeping us on track for our projected milestones."

About Glafabra Therapeutics

Glafabra is a gene therapy company focused on highly effective, redosable treatments where one dose lasts for years, not weeks. Its lead asset (GT-GLA-S03) is designed to provide comprehensive care at a more affordable price than traditional gene therapies. Building on the success of the Canadian Fabry disease trial (PMID 39794302), Glafabra is currently seeking to close its $1M pre-seed round by Q1 and leverage existing clinical data toward an open IND and a U.S. clinical trial start in early 2027.